Our antibody drug discovery platforms, utilizing Ablexis’ AlivaMab^® Mouse, are optimized for the discovery of therapeutic antibodies that move seamlessly into development. Accelerated timelines and reduced developability risks are achieved with naturally selected fully human variable domains, advanced antibody discovery workflows, integration of reliable, predictive screening cascades, and rapid identification of candidates that meet target product profile requirements.